Tacrolimus Ointment: A Topical Immunomodulator for Atopic Dermatitis, Volume 1
Thomas Ruzicka, Sakari Reitamo
Springer, 2004 - Medical - 279 pages
Therapeutic breakthroughs in medicine are usually accompanied by a wealth of data. Often they result in a change of disease treatment paradigms. Tacrolimus ointment is the first in the new class of steroid-free Topical Immunomodulators (TIMs), and as such represents the first true breakthrough since the introduction of topical steroids more than 50 years ago for the treatment of T-cell mediated inflammatory skin diseases such as atopic dermatitis. This book gives an easy-to-read overview of the discovery and the development of Tacrolimus ointment for the treatment of atopic dermatitis. Summarising the largest clinical trial program ever conducted in dermatology for a new treatment with more than 13000 patients, it offers a detailed insight into the efficacy and safety profile of Tacrolimus ointment. Based on this large body of data and extensive personal experience, the authors offer practical and hands-on guidance for the physician as to when and how to use Tacrolimus ointment in daily practice.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Epidemiology of Atopic Dermatitis
Age of Onset and Concomitant Atopy
Immunology and Infections
31 other sections not shown
Other editions - View all
Tacrolimus Ointment: A Topical Immunomodulator for Atopic Dermatitis
T. Ruzicka,S. Reitamo
Limited preview - 2013
activation adults adverse events agents allergens Allergy Allergy Clin Immunol antigen Arch Dermatol areas assessed asthma atopic dermatitis atopic dermatitis patients atopic diseases atopic eczema atopy aureus CDLQI chronic clinical trials corticosteroids costs criteria cutaneous cyclosporin cytokines dendritic cells Dermatology diagnostic DLQI drug effects of tacrolimus efficacy of tacrolimus epidermal evaluation factors FceRI gene genetic glucocorticosteroids GVHD hydrocortisone IDQOL immunomodulators immunomodulatory immunosuppressive improvement increased Index infections inflammatory skin inhibition Invest Dermatol Langerhans cells lesions long-term lymphocytes management of atopic mast cells matitis mEASI ment mild moderate to severe paediatric patients with atopic Pharmacokinetics potential prevalence Protopic pruritus psoriasis pyoderma gangrenosum QoL measurements questionnaire receptor reduced Reitamo risk role safety SCORAD score sensitisation severe atopic dermatitis side effects skin atrophy skin disease specific steroids superantigens symptoms T-cell tacro tacrolimus ointment therapeutic therapy topical corticosteroids topical tacrolimus transplantation treated treatment of atopic vehicle vitro